Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era
Sarah Twigg,Elizabeth M A Hensor,Jane Freeston,Ai Lyn Tan,Paul Emery,Alan Tennant,Ann W Morgan,YEAR and IACON Consortia,Philip Conaghan,Anne-Maree Keenan,Elizabeth Hensor,Mark Quinn,Andrew Gough,Michael Green,Richard Reece,Lesley Hordon,Philip Helliwell,Richard Melsom,Sheelagh Doherty,Ade Adebajo,Andrew Harvey,Steve Jarrett,Gareth Huston,Amanda Isdale,Mike Martin,Zunaid Karim,Dennis McGonagle,Colin Pease,Sally Cox,Victoria Bejarano,Jackie Nam,Edith Villeneuve,Claire Brown,Christine Thomas,David Pickles,Alison Hammond,Beverley Neville,Alan Fairclough,Caroline Nunns,Anne Gill,Julie Green,Belinda Rhys-Evans,Barbara Padwell,Julie Madden,Lynda Taylor,Sally Smith,Heather King,Jill Firth,Jayne Heard,Linda Sigsworth,Diane Corscadden,Karen Henshaw,Lubna-Haroon Rashid,Stephen Martin,James Robinson,Lukasz Kozera,Agata Burksa,Sarah Fahy,Andrea Paterson,Frederique Ponchel,Maya Buch,Jacqueline Andrews,Richard Wakefield,Denis McGonagle,Helena Marzo-Ortega,Sudipto Das,Sarah Horton,Sarah Mackie,Rebecca Thomas,Lesley Ann Bissell,Chadi Rakieh,Zoe Ash,Amir Aslam,Benazir Saleem,Laura Coates,Fahad Fazal,Laura Hunt,Ed Vital,Esme Ferguson,Sara Else,Gui Tran,Ahmed Zayat,Guiseppina Abignano,Yuz Yousef,Radhika Raghunath,Hannah Mathieson,Chitra Ramakumain,Hanna Gul,Mahwish Mahmood,Pauline Fitzgerald,Matthew Robinson,Jason Ward,Beverly Wells,Oliver Wordsworth,Alison McManus,Lynda Bailey,Linda Gray,Kate Russell,Jayne Davies,Katie Mbara,Jill Halsted-Rastrick,Ged Connoly-Thompson,Jonathan Thompson,Ian Weatherill,Laura Horton,Alwyn Jackson,Richard Hodgson
DOI: https://doi.org/10.1002/acr.23281
Abstract:Objective: To compare disease activity and disability over 2 years in early rheumatoid arthritis (RA) before and after implementation of treat-to-target therapy and identify predictors of adverse outcome. Methods: The Yorkshire Early Arthritis Register (YEAR) recruited 725 patients with early RA between 2002 and 2009, treated with a step-up approach. The Inflammatory Arthritis Continuum study (IACON) recruited cases between 2010 and 2014 and treated to target. A total of 384 IACON cases met 2010 American College of Rheumatology/European League Against Rheumatism criteria. Latent growth curves of change in Disease Activity Score in 28 joints (DAS28) and the Health Assessment Questionnaire (HAQ) were compared between YEAR and IACON. Latent class growth analysis identified trajectories of change. Baseline predictors of trajectories were identified using logistic regression. Results: The mean DAS28 over 2 years was lower in IACON than in YEAR. Latent trajectories of HAQ change in YEAR were high stable (21% of cohort), moderate reducing (35%), and low reducing (44%). Only moderate reducing (66%) and low reducing (34%) were seen in IACON. In both cohorts, female sex and fatigue predicted adverse HAQ trajectories (high stable and moderate reducing). Odds ratios (ORs) for moderate reducing compared to low reducing for women were 2.58 (95% confidence interval [95% CI] 1.69, 4.49) in YEAR and 5.81 (95% CI 2.44, 14.29) in IACON. ORs per centimeter fatigue visual analog score were 1.13 (95% CI 1.07, 1.20) in YEAR and 1.16 (95% CI 1.12, 1.20) in IACON. Conclusion: Treat-to-target therapy gave more favorable trajectories of change in DAS28 and HAQ, but adverse HAQ trajectory was more likely in women with greater fatigue, suggesting such patients would benefit from interventions to improve function as well as reduce inflammation.